Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4481-4484

  Keskikuru, Riitta ^a   Kataja, Vesa ^a   Kosma, Veli Matti ^a   Eskelinen, Matti ^a   Uusitupa, Matti ^a   Johansson, Risto ^a   Risteli, Leila ^a   Risteli, Juha ^c   Jukkola, Arja ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c NONE

Author keywords

Advanced breast cancer; ICTP; PICP; PINP; Type I collagen markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAGEN TYPE 1;

ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER STAGING; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

BREAST DISEASES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0033404362     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Van der Rest M, Garrone R: Collagen family of proteins. FASEB J 5: 2814-2823, 1991.
2. Risteli J, Niemi S, Kauppila S. Melkko J, Risteli L: Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand 66: 1-6, 1995.
3. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br JCancer 73: 1074-1079, 1996.
4. Tahtela R, Tholix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16: 2289-2294, 1996.
5. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39/4: 635-640, 1993.
6. Risteli L, Risteli J: Biochemical markers of bone metabolism. Ann Med 25: 385-393, 1993.
7. Jukkola A, Tahtela R, Tholix E, Vuorinen K, Blanco G, Risteli L, Risteli J: Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57: 5517-5520, 1997.
8. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332, 1990.
9. Melkko J, Kauppila S, Risteli L, Niemi S, Haukipuro K, Jukkola A, Risteli J: Immunoassay for intact aminoterminal propeptide of type I procollagen. Clin Chem 42: 947-954, 1996.
10. Tahtela R, Turpeinen M, Sorva R, Karonen S-L: The aminoterminal propeptide of type I procollagen, evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin Biochem 30(1): 35-40, 1997.
11. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I: Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061-1064, 1995.
12. Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T, Ogata E: Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 75 (11): 1601-1604, 1997.
13. Body JJ, Dumon JC, Gineyts E, Delmas PD: Comparative evalution of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75(3): 408-412, 1997.
14. Coleman RE, Purohit OP, Vinholes JJ, Zekri J: High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer Oct 15, 80 (8 Suppl): 1686-1690, 1997.
15. Sharp CA, Davie MWJ, Worsfold M, Risteli L, Risteli J: Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone.[Letter] Clin Chem 42: 1121-1122, 1996.
16. Pucci-Minafra I, Andrialo M, Basirilo L, Aquino A, Minafra S, Boutillon M-M, Vander Rest M: Onco-fetal/laminin-binding collagen from colon carcinoma. Detection of new sequences. Biochem Biophys Res Commun 207: 852-859, 1995.
17. Luparello C, Sheterline P, Pucci-Minafra I, Minafra S: A comparison of spreading and motility behaviour of 8701-BC breast carcinoma cells on type I, α1-trimer and type V collagen substrata. Evidence for a permissive effect of type 1-trimer collagen on cell locomotion. J Cell Science 100: 179-185, 1991
18. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA, Chevallier M: The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoing liver fibrosis. Clin Chem Acta 30; 248(2): 187-95, 1996.
19. Hayes DF: Tumor markers for breast cancer. Ann Oncol 4: 807-819, 1993.
20. Eskelinen M, Kataja V, Hamalainen E, Kosma VM, Penttila I, Alhava E: Serum tumour markers CEA, AFP, CA 15-3, TPR and NEU in diagnosis of breast cancer. Anticancer Res 17: 1231-1234, 1997.
21. Safi F, Kohler I, Rottinger E, Beger H-G: The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer 68: 574-582, 1991.
22. Tampelini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L: Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75(5): 698-702, 1997.